Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB2 | P47870 | 2/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.52 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | KIF11 | P52732 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | XPO1 | O14980 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861023 | 1.00 | GABRB2 (0.52) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL15077166 | 0.92 | GABRB2 (0.46) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL1754077 | 0.89 | GABRA1 (0.44) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL21715549 | 0.89 | GABRA1 (0.44) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL3439602 | 0.89 | RAPGEF4 (0.48) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL18077879 | 0.87 | GABRB2 (0.42) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL14200010 | 0.87 | MAPK1 (0.46) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL21233217 | 0.87 | KIF11 (0.42) | GABRB2GABRA1CES2KIF11POLB | |
| SCHEMBL18353568 | 0.87 | GABRA1 (0.76) | GABRB2GABRA1CES2KIF11IDO1 | |
| SCHEMBL1104681 | 0.87 | NOTUM (0.47) | GABRB2GABRA1CES2KIF11POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239793-A1 | PROCESS FOR PREPARING PEXIDARTINIB | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2024-07-18 | — | — | US | disclosed |
| US-20240239793-A1 | PROCESS FOR PREPARING PEXIDARTINIB | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2024-07-18 | — | — | US | disclosed |
| EP-3681928-B1 | PROCESS OF MANUFACTURING POLYOLS | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11912822-B2 | Process of manufacturing polyols | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-02-27 | — | — | US | disclosed |
| US-11873426-B2 | Curable composition, cured product, optical member, lens, and compound | FUJIFILM CORPORATION (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11873426-B2 | Curable composition, cured product, optical member, lens, and compound | FUJIFILM CORPORATION (JP) | 2024-01-16 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11832510-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230357632-A1 | IONIC LIQUID PEROVSKITE DEVICES | CUBICPV INC. | 2023-11-09 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7226950-B2 | Sodium channel modulators | THERAVANCE, INC. (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2007-05-31 | — | — | US | disclosed |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2007-05-31 | — | — | US | disclosed |
| US-7214668-B2 | Phosphonic acid based prodrugs of PMEA and its analogues | METABASIS THERAPEUTICS, INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CHEMOCENTRYX, INC. | 2007-02-15 | — | — | US | disclosed |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GABRB2 4164/4885GABRA1 4260/4885CES2 58/4885 |
| US-11832510-B2 | Organic electroluminescent materials and devices | OSBP, OCIAD2, OCIAD1 | GABRB2 3585/4885GABRA1 4296/4885CES2 110/4885 |
| US-20040082578-A1 | Arylindenopyridines and related therapeutic and prophylactic methods | ADORA2A, ADORA1, PDE2A | GABRB2 386/4885GABRA1 500/4885CES2 454/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | GABRB2 4164/4885GABRA1 4260/4885CES2 58/4885 |
| US-20070037794-A1 | 4-((5-Chloro-3-(4-methyl-3-trifluoromethylbenzenesulfonylamino)pyridin-2-yl)-oxo-)1H-pyrrolo(2,3-)pyridine;interfere with ligand (monocyte chemoatactic protein-1) for chemokine receptors (CCR2); antiinflammatory agents; immunomodulators; bactericides; viricides; fungicides | CCR2, CCR1, CCL2 | GABRB2 1115/4885GABRA1 659/4885CES2 854/4885 |
| US-11912822-B2 | Process of manufacturing polyols | MRPL21, RER1, PCBP1 | GABRB2 2107/4885GABRA1 1584/4885CES2 906/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | GABRB2 435/4885GABRA1 1294/4885CES2 645/4885 |
| US-20070123576-A1 | Compounds inducing differentiation of myoblasts or muscle fibers into neuron cells, pharmaceutical composition including said compounds, a method for inducing neuron differentiation and a screening method for identifying additional compounds useful for inducing neuron differentiation | TNNC1, TNNI3, PYGM | GABRB2 690/4885GABRA1 1541/4885CES2 1283/4885 |
| US-11873426-B2 | Curable composition, cured product, optical member, lens, and compound | RB1, CCNO, SPOP | GABRB2 2862/4885GABRA1 2189/4885CES2 4119/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | GABRB2 840/4885GABRA1 1992/4885CES2 900/4885 |
| US-20240239793-A1 | PROCESS FOR PREPARING PEXIDARTINIB | F9, FLT3, F12 | GABRB2 3626/4885GABRA1 2629/4885CES2 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.